IQVIA and Kexing Biopharm have announced an expansion of their strategic collaboration to support a global, multi-product biosimilar development and commercialization program.
Enhancing Efficiency Through AI Integration The core of this partnership lies in the integration of IQVIA’s AI-enabled clinical trial capabilities across the entire development lifecycle. By leveraging AI from protocol design and site identification to study execution, the collaboration aims to:
-
Accelerate the speed and efficiency of clinical trials.
-
Enhance confidence in data-driven decision-making throughout development.
-
Mitigate regulatory risks and streamline overseas registration processes.
Strategic Global Expansion By uniting IQVIA’s advanced analytics and global regulatory expertise with Kexing’s biosimilar portfolio, the program is designed to bring high-quality biological treatments to international markets more rapidly. Kexing Biopharm’s leadership expressed high confidence that IQVIA’s global data resources and patient insights will serve as a crucial catalyst for the company’s internationalization strategy.